FR2960876B1 - Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. - Google Patents

Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Info

Publication number
FR2960876B1
FR2960876B1 FR1054372A FR1054372A FR2960876B1 FR 2960876 B1 FR2960876 B1 FR 2960876B1 FR 1054372 A FR1054372 A FR 1054372A FR 1054372 A FR1054372 A FR 1054372A FR 2960876 B1 FR2960876 B1 FR 2960876B1
Authority
FR
France
Prior art keywords
dihydropyrrolo
pyrazine
preparation
therapeutic use
dicarboxamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1054372A
Other languages
English (en)
Other versions
FR2960876A1 (fr
Inventor
Jacques Froissant
Jean Francois Gibert
Frank Marguet
Christophe Pacaud
Frederic Puech
Antoine Ravet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2960876(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1054372A priority Critical patent/FR2960876B1/fr
Priority to MX2012014084A priority patent/MX2012014084A/es
Priority to SI201131022A priority patent/SI2588480T1/sl
Priority to PE2012002257A priority patent/PE20130259A1/es
Priority to BR112012030697A priority patent/BR112012030697A2/pt
Priority to HUE11781590A priority patent/HUE030650T2/en
Priority to DK11781590.2T priority patent/DK2588480T3/en
Priority to PL11781590T priority patent/PL2588480T3/pl
Priority to NZ603947A priority patent/NZ603947A/en
Priority to PT117815902T priority patent/PT2588480T/pt
Priority to CN201180038277.8A priority patent/CN103168041B/zh
Priority to ES11781590.2T priority patent/ES2603420T3/es
Priority to EP11781590.2A priority patent/EP2588480B1/fr
Priority to EA201291364A priority patent/EA201291364A1/ru
Priority to KR1020127031424A priority patent/KR20130113928A/ko
Priority to SG2012088795A priority patent/SG186143A1/en
Priority to LTEP11781590.2T priority patent/LT2588480T/lt
Priority to JP2013513006A priority patent/JP5995841B2/ja
Priority to AU2011268651A priority patent/AU2011268651B2/en
Priority to CA2801154A priority patent/CA2801154C/fr
Priority to MA35524A priority patent/MA34360B1/fr
Priority to PCT/IB2011/001594 priority patent/WO2011161537A2/fr
Priority to ARP110101901A priority patent/AR081832A1/es
Priority to TW100119696A priority patent/TWI487707B/zh
Priority to UY0001033428A priority patent/UY33428A/es
Publication of FR2960876A1 publication Critical patent/FR2960876A1/fr
Publication of FR2960876B1 publication Critical patent/FR2960876B1/fr
Application granted granted Critical
Priority to TNP2012000520A priority patent/TN2012000520A1/en
Priority to DO2012000296A priority patent/DOP2012000296A/es
Priority to CR20120595A priority patent/CR20120595A/es
Priority to GT201200319A priority patent/GT201200319A/es
Priority to IL223364A priority patent/IL223364A/en
Priority to US13/688,916 priority patent/US8791119B2/en
Priority to NI201200176A priority patent/NI201200176A/es
Priority to CL2012003360A priority patent/CL2012003360A1/es
Priority to ZA2012/09071A priority patent/ZA201209071B/en
Priority to CO12218640A priority patent/CO6602113A2/es
Priority to ECSP12012322 priority patent/ECSP12012322A/es
Priority to US14/339,112 priority patent/US9233965B2/en
Priority to HRP20161494TT priority patent/HRP20161494T1/hr
Priority to CY20161101179T priority patent/CY1118512T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
FR1054372A 2010-06-03 2010-06-03 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. Expired - Fee Related FR2960876B1 (fr)

Priority Applications (39)

Application Number Priority Date Filing Date Title
FR1054372A FR2960876B1 (fr) 2010-06-03 2010-06-03 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
MA35524A MA34360B1 (fr) 2010-06-03 2011-06-01 Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide, préparation de ceux-ci et utilisation thérapeutique de ceux-ci et utilisation thérapeutique de ceux-ci
PCT/IB2011/001594 WO2011161537A2 (fr) 2010-06-03 2011-06-01 Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide, leur préparation et leur utilisation thérapeutique
PE2012002257A PE20130259A1 (es) 2010-06-03 2011-06-01 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparacion y su uso terapeutico
SI201131022A SI2588480T1 (sl) 2010-06-03 2011-06-01 Derivati 3,4-dihidropirolo(1,2-a)pirazina-2,8(1H)-dikarboksamida, njihova priprava in terapevtska uporaba
HUE11781590A HUE030650T2 (en) 2010-06-03 2011-06-01 3,4-Dihydropyrrolo [1,2-A] pyrazine-2,8 (1H) -dicarboxamide derivatives, process for their preparation and therapeutic use
DK11781590.2T DK2588480T3 (en) 2010-06-03 2011-06-01 3,4-dihydro-pyrrolo [1,2-a] pyrazine-2,8 (1H) -DICARBOXAMIDDERIVATER PREPARATION AND THERAPEUTIC USE THEREOF
PL11781590T PL2588480T3 (pl) 2010-06-03 2011-06-01 Pochodne 3,4-dihydropirolo[1,2-a]pirazyno-2,8(1H)-dikarboksyamidowe, ich otrzymywanie i zastosowania terapeutyczne
NZ603947A NZ603947A (en) 2010-06-03 2011-06-01 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
PT117815902T PT2588480T (pt) 2010-06-03 2011-06-01 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)dicarboxamida, sua preparação e sua utilização terapêutica
CN201180038277.8A CN103168041B (zh) 2010-06-03 2011-06-01 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途
ES11781590.2T ES2603420T3 (es) 2010-06-03 2011-06-01 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1H)-dicarboxamida, su preparación y uso terapéutico de los mismos
EP11781590.2A EP2588480B1 (fr) 2010-06-03 2011-06-01 Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide, leur préparation et leur utilisation thérapeutique
EA201291364A EA201291364A1 (ru) 2010-06-03 2011-06-01 Производные 3,4-дигидропирроло[1,2-а]пиразин-2,8(1н)-дикарбоксамида, их получение и применение в терапии
KR1020127031424A KR20130113928A (ko) 2010-06-03 2011-06-01 3,4-디히드로피롤로[1,2-ａ]피라진-2,8(1Ｈ)-디카르복스아미드 유도체, 그의 제조법 및 그의 치료 용도
SG2012088795A SG186143A1 (en) 2010-06-03 2011-06-01 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
LTEP11781590.2T LT2588480T (lt) 2010-06-03 2011-06-01 3,4-dihidropolo[1,2-a]pirazin-2,8(1h)-dikarboksamido dariniai, jų gamyba ir terapinis panaudojimas
JP2013513006A JP5995841B2 (ja) 2010-06-03 2011-06-01 ３，４−ジヒドロピロロ［１，２−ａ］ピラジン−２，８（１Ｈ）−ジカルボキサミド誘導体、その調製、およびその治療的使用
AU2011268651A AU2011268651B2 (en) 2010-06-03 2011-06-01 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
CA2801154A CA2801154C (fr) 2010-06-03 2011-06-01 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide, leur preparation et leur utilisation therapeutique
MX2012014084A MX2012014084A (es) 2010-06-03 2011-06-01 Deivados de 3, 4-dihidropirrolo [1, 2-a] pirazina-2, 8 (1h) -dicarboxamida su preparacion y sus uso terapeutico.
BR112012030697A BR112012030697A2 (pt) 2010-06-03 2011-06-01 derivados de 3,4-di-hidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, preparação destes e emprego terapêutico destes
ARP110101901A AR081832A1 (es) 2010-06-03 2011-06-02 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, su preparacion y su aplicacion en terapeutica
UY0001033428A UY33428A (es) 2010-06-03 2011-06-03 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparacion y su aplicacion en terapeutica
TW100119696A TWI487707B (zh) 2010-06-03 2011-06-03 ３，４－二氫吡咯并［１，２－ａ］吡－２，８（１ｈ）－二碳醯胺衍生物及其製備與治療用途
TNP2012000520A TN2012000520A1 (en) 2010-06-03 2012-10-31 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
DO2012000296A DOP2012000296A (es) 2010-06-03 2012-11-22 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparación y su uso terapéutico
CR20120595A CR20120595A (es) 2010-06-03 2012-11-26 Derivados de 3,4-dihidropirrolo[1,2-a] pirazina-2,8 (1h)-dicarboxamida su preparación y su uso terapéutico
GT201200319A GT201200319A (es) 2010-06-03 2012-11-27 Derivados de 3, 4-dihidropirrolo [1, 2 -a ] pirazina - 2, 8(1h)- dicarboxamida su preparacion y su uso terapèutico
IL223364A IL223364A (en) 2010-06-03 2012-11-29 Derivatives of 4,3-Dihydro-pyrrolo [2,1-a] pyrene 2,8 (1 h) - dicarboxamide, their preparation, and their medical use
US13/688,916 US8791119B2 (en) 2010-06-03 2012-11-29 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta
ZA2012/09071A ZA201209071B (en) 2010-06-03 2012-11-30 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
CL2012003360A CL2012003360A1 (es) 2010-06-03 2012-11-30 Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, inhibidores de caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; medicamento que los comprende; composición farmacéutica; y su uso para prevenir o tratar trastornos del sueño y del ritmo circadíano, y enfermedades inflamatorias.
NI201200176A NI201200176A (es) 2010-06-03 2012-11-30 Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico.
ECSP12012322 ECSP12012322A (es) 2010-06-03 2012-12-03 Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparación y su uso terapéutico
CO12218640A CO6602113A2 (es) 2010-06-03 2012-12-03 Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéutico
US14/339,112 US9233965B2 (en) 2010-06-03 2014-07-23 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta
HRP20161494TT HRP20161494T1 (hr) 2010-06-03 2016-11-11 Derivati 3,4-dihidropirolo[1,2-a]pirazin-2,8(1h)-dikaboksamida, njihova priprava i terapijska primjena
CY20161101179T CY1118512T1 (el) 2010-06-03 2016-11-16 Παραγωγα 3,4-διϋδροπυρρολο[1,2-α]πυραζινο-2,8(1η)-δικαρβοξαμιδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1054372A FR2960876B1 (fr) 2010-06-03 2010-06-03 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Publications (2)

Publication Number Publication Date
FR2960876A1 FR2960876A1 (fr) 2011-12-09
FR2960876B1 true FR2960876B1 (fr) 2012-07-27

Family

ID=42697541

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1054372A Expired - Fee Related FR2960876B1 (fr) 2010-06-03 2010-06-03 Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Country Status (38)

Country Link
US (2) US8791119B2 (fr)
EP (1) EP2588480B1 (fr)
JP (1) JP5995841B2 (fr)
KR (1) KR20130113928A (fr)
CN (1) CN103168041B (fr)
AR (1) AR081832A1 (fr)
AU (1) AU2011268651B2 (fr)
BR (1) BR112012030697A2 (fr)
CA (1) CA2801154C (fr)
CL (1) CL2012003360A1 (fr)
CO (1) CO6602113A2 (fr)
CR (1) CR20120595A (fr)
CY (1) CY1118512T1 (fr)
DK (1) DK2588480T3 (fr)
DO (1) DOP2012000296A (fr)
EA (1) EA201291364A1 (fr)
EC (1) ECSP12012322A (fr)
ES (1) ES2603420T3 (fr)
FR (1) FR2960876B1 (fr)
GT (1) GT201200319A (fr)
HR (1) HRP20161494T1 (fr)
HU (1) HUE030650T2 (fr)
IL (1) IL223364A (fr)
LT (1) LT2588480T (fr)
MA (1) MA34360B1 (fr)
MX (1) MX2012014084A (fr)
NI (1) NI201200176A (fr)
NZ (1) NZ603947A (fr)
PE (1) PE20130259A1 (fr)
PL (1) PL2588480T3 (fr)
PT (1) PT2588480T (fr)
SG (1) SG186143A1 (fr)
SI (1) SI2588480T1 (fr)
TN (1) TN2012000520A1 (fr)
TW (1) TWI487707B (fr)
UY (1) UY33428A (fr)
WO (1) WO2011161537A2 (fr)
ZA (1) ZA201209071B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
AR098414A1 (es) * 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
JP6307989B2 (ja) * 2014-04-02 2018-04-11 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
WO2018189214A1 (fr) 2017-04-12 2018-10-18 F. Hoffmann-La Roche Ag Procédé de marquage de molécules cibles contenant un aldéhyde
US11247998B2 (en) * 2017-07-27 2022-02-15 Jiangsu Hengrui Medicine Co., Ltd. Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
WO2024002157A1 (fr) * 2022-06-29 2024-01-04 Insilico Medicine Ip Limited Inhibiteurs de fgfr2 et de fgfr3 et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100668006B1 (ko) 1999-02-01 2007-01-15 유니버시티 오브 버지니아 페이턴트 파운데이션 염증 반응을 치료하기 위한 조성물
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL1747220T3 (pl) 2003-12-11 2009-09-30 Aventis Pharma Inc Podstawione 1H-pirolo[3,2-b, 3,2-c i 2,3-c]pirydyno-2-karboksyamidy oraz pokrewne analogi jako inhibitory kinazy kazeinowej l epsilon
GB0328900D0 (en) 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
WO2008147713A1 (fr) * 2007-05-24 2008-12-04 The Regents Of The University Of California Inhibiteurs de souligné de wnt et procédés de préparation et d'utilisation de ceux-ci
MX2010001076A (es) * 2007-07-27 2010-03-09 Sanofi Aventis Derivados de 1,2,3,4-tetrahidropirrolo-[1,2-a]-pirazina-6-carboxam ida y 2,3,4,5-tetrahidropirrollo [1,2,a] [1,4]-diazepina-7-carboxa mida, preparacion y su uso terapeutico.
CA2712265A1 (fr) * 2008-01-17 2009-07-23 Gruenenthal Gmbh Derives de sulfonamide substitues
US20090192147A1 (en) * 2008-01-30 2009-07-30 Wyeth [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
AR081832A1 (es) 2012-10-24
TN2012000520A1 (en) 2014-04-01
EA201291364A1 (ru) 2013-05-30
WO2011161537A3 (fr) 2012-03-01
US20130090340A1 (en) 2013-04-11
DOP2012000296A (es) 2013-02-28
US20140336189A1 (en) 2014-11-13
CA2801154C (fr) 2018-01-09
WO2011161537A2 (fr) 2011-12-29
MA34360B1 (fr) 2013-07-03
IL223364A (en) 2015-06-30
CL2012003360A1 (es) 2013-04-01
ZA201209071B (en) 2014-02-26
TW201202248A (en) 2012-01-16
CN103168041A (zh) 2013-06-19
SI2588480T1 (sl) 2016-12-30
ECSP12012322A (es) 2013-03-28
CY1118512T1 (el) 2017-07-12
CN103168041B (zh) 2015-08-26
LT2588480T (lt) 2016-12-12
PT2588480T (pt) 2016-11-21
CA2801154A1 (fr) 2011-12-29
MX2012014084A (es) 2013-01-29
FR2960876A1 (fr) 2011-12-09
BR112012030697A2 (pt) 2019-09-24
EP2588480A2 (fr) 2013-05-08
PL2588480T3 (pl) 2017-08-31
GT201200319A (es) 2014-01-17
KR20130113928A (ko) 2013-10-16
NZ603947A (en) 2014-12-24
JP2013527226A (ja) 2013-06-27
UY33428A (es) 2011-12-30
US8791119B2 (en) 2014-07-29
TWI487707B (zh) 2015-06-11
EP2588480B1 (fr) 2016-08-17
AU2011268651A1 (en) 2012-12-20
ES2603420T3 (es) 2017-02-27
US9233965B2 (en) 2016-01-12
CO6602113A2 (es) 2013-01-18
HRP20161494T1 (hr) 2016-12-16
CR20120595A (es) 2013-01-03
DK2588480T3 (en) 2016-12-12
PE20130259A1 (es) 2013-03-22
NI201200176A (es) 2013-02-06
AU2011268651B2 (en) 2016-09-01
SG186143A1 (en) 2013-01-30
JP5995841B2 (ja) 2016-09-21
HUE030650T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
FR2918061B1 (fr) Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2918986B1 (fr) Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
FR2928922B1 (fr) Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928924B1 (fr) Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2962437B1 (fr) Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2928921B1 (fr) Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2943058B1 (fr) Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2960876B1 (fr) Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
FR2887882B1 (fr) Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2955109B1 (fr) Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2906251B1 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
FR2925903B1 (fr) DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2930939B1 (fr) Derives de pyrrole, leur preparation et leur application en therapeutique
FR2919610B1 (fr) Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20170228